400客服电话
购买数据产品
400-9696-311 转1
定制咨询业务
400-9696-311 转2
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
ChiCTR2600118222
尚未开始
/
/
/
2026-02-03
/
/
Diabetes Mellitus
A self-determination theory-based interprofessional intervention to improve diabetes management in the primary health care setting of Hong Kong
A self-determination theory-based interprofessional intervention to improve diabetes management in the primary health care setting of Hong Kong
1.Comparing with the control group (CG) receiving conventional didactic information, the IPE-SDT intervention group shows significant improvement on HbA1C levels. 2.The utilisation of public medical resources including accident & emergency room visit, clinic visit, and hospital admissions for diabetes-related matters in the IPE-SDT intervention group will be less than the CG. 3.The SDT-IPE educational intervention has positive effect on subjects’ psychological factors of perceived autonomy, competency, and relatedness that can result in changes in their motivation and engagement and lead to changes in health behaviours that could impact on their health status (both physical and psychological well-being) after they have received the 3-month educational program.
随机平行对照
其它
The current study adopted the RCT study design. Eligible students will be randomly assigned (1:1) with a computer-generated list of random numbers to one of the two groups.
N/A
General Research Fund (GRF), University Grants Committee, Hong Kong
/
80
/
2025-01-01
2027-06-30
/
1. All male or female Chinese newly diagnosed DM subjects aged between 45-70 years old; 2. Able to give informed consent.；
请登录查看1. Patients who have dementia and/or cannot understand Cantonese; 2. Patients who have gestational diabetes; 3. Concurrently involved in another clinical trial, educational/behavioural modification intervention program；
请登录查看General Research Fund (GRF), University Grants Committee, Hong Kong
/
求实药社2026-07-16
医药观澜2026-07-16
BioArt2026-07-16
一度医药2026-07-16
医药笔记2026-07-16
医药笔记2026-07-16
杏泽资本2026-07-16
药明康德2026-07-16
中国北京同仁堂官微2026-07-15
400-9696-311 转1
400-9696-311 转3
400-9696-311 转4
400-9696-311 转5
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
“坚决打赢禁毒人民战争”专栏 法律法规 | 美、墨、欧盟管制品种
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
